Clinical Trial

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

Study acronym: CREAATE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant IR capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.
Protocol Amendment History 2 changes
notable Trial sites expanded: 17 -> 32 locations 2026-06-27
notable Trial sites expanded: 7 -> 17 locations 2026-05-08
Trial Details
NCT Number NCT07266805
Lead Sponsor Pharvaris Netherlands B.V.
Conditions Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Enrollment 32 participants
Start Date 2025-10-16
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-29